“Ebola left a devastating legacy in our country. We are proud that we have been able to contribute to developing a vaccine that will prevent other nations from enduring what we endured,” said Dr. KeÏta Sakoba, the director of the national agency for health security in Guinea.
The experimental vaccine was given in 2015 to people in Guinea who were in contact with patients who had recently confirmed cases of Ebola.
A few months after the early trials, the World Health Organization said the preliminary results were an “extremely promising development.”
The trial involved more than 11,000 people, according to the WHO, which led the trial in conjunction with Guinea’s Ministry of Health.
The vaccine was manufactured by Merck, Sharp & Dohme and is being fast-tracked by US and European regulatory agencies.
Merck has promised to ensure that 300,000 doses of the vaccine will be available in case of a new Ebola flareup. It will submit the vaccine for licensing by the close of 2017.